The role of surgeons in building a personalized medicine program

Journal of Surgical Oncology

Volumn 111, Issue 1, 2015, Pages 3-8

  Boland, Genevieve M ^a   Meric Bernstam, Funda ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Genomics; Next generation sequencing; Personalized medicine; Precision medicine

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; MICRORNA; PROTEIN; RNA;

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURGERY; CANCER TISSUE; CAPILLARY ELECTROPHORESIS; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL DECISION MAKING; DNA SEQUENCE; EARLY DIAGNOSIS; EXOME; EXOSOME; GENE EXPRESSION; GENE IDENTIFICATION; GENOME ANALYSIS; HEALTH CARE FACILITY; HUMAN; NEXT GENERATION SEQUENCING; ONCOGENE; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PYROSEQUENCING; REVIEW; SURGEON; SURGICAL TECHNIQUE; TISSUE PRESERVATION; TUMOR BIOPSY; GENETICS; GENOMICS; HEALTH CARE DELIVERY; HUMAN GENOME; NEOPLASMS; PHYSICIAN ATTITUDE;

DELIVERY OF HEALTH CARE; GENOME, HUMAN; GENOMICS; HUMANS; NEOPLASMS; PHYSICIAN'S ROLE; PRECISION MEDICINE; SURGEONS;

EID: 84920142851     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23684     Document Type: Review

References (30)

1. Paik S, Hazan R, Fisher ER, et al.: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-112.
2. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
3. Shaw AT, Yeap BY, Solomon BJ, et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 2011;12:1004-1012.
4. Laurent-Puig P, Cayre A, Manceau G, et al.: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-5930.
5. Tsimberidou AM, Ringborg U, Schilsky RL: Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.AmSoc Clin Oncol Educ Book 2013;33:118-125.
6. Cronin M, Ross JS: Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med 2011;5:293-305.
7. Meric-Bernstam F, Farhangfar C, Mendelsohn J, et al.: Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 2013;31:1849-1857.
8. Schwarzenbach H, Hoon DS, Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-437.
9. Umovitz HBBJ, Schutz E, Singh G, et al.: Modulation of breast cancer cell-free DNA with surgical resection. J Clin Oncol 2013;31: Abstr 11060.
10. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
11. Mitchell PS, Parkin RK, Kroh EM, et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-10518.
12. Borges FT, Melo SA, Ozdemir BC, et al.: TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol 2013;24:385-392.
13. Peinado H, Aleckovic M, Lavotshkin S, et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012;18:883-891.
14. Schaeffer D, Reis FP, Johnson SJ, et al.: The CR3 motif of Rrp44p is important for interaction with the core exosome and exosome function. Nucleic Acids Res 2012;40:9298-9307.
15. Kahlert C, Melo SA, Protopopov A, et al.: Identification of double stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 2014;289:3869-3875.
16. Cristofanilli M, Budd GT, Ellis MJ, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
17. Lucci A, Hall CS, Lodhi AK, et al.: Circulating tumour cells in nonmetastatic breast cancer: A prospective study. Lancet Oncol 2012;13:688-695.
18. Mroz EA, Tward AD, Pickering CR, et al.: High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 2013;119:3034-3042.
19. Nikiforov YE, Ohori NP, Hodak SP, et al.: Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011;96:3390-3397.
20. Nikiforova MN, Nikiforov YE: Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009;19:1351-1361.
21. Wu J, Matthaei H, Maitra A, et al.: Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3:92ra66.
22. Cabioglu N, Hunt KK, Sahin AA, et al.: Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol 2007;14:1458-1471.
23. Haka AS, Volynskaya Z, Gardecki JA, et al.: In vivo margin assessment during partial mastectomy breast surgery using Raman spectroscopy. Cancer Res 2006;66:3317-3322.
24. Karni T, Pappo I, Sandbank J, et al.: A device for real-time, intraoperative margin assessment in breast-conservation surgery. Am J Surg 2007;194:467-473.
25. Goldenberg D, Harden S, Masayesva BG, et al.: Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:39-44.
26. Boland GM, Gershenwald JE: Sentinel lymph node biopsy in melanoma. Cancer J 2012;18:185-191.
27. Mamounas EP, Tang G, Fisher B, et al.: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677-1683.
28. Webber EM, Lin JS, Evelyn PW: Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: Prognostic, risk prediction. Version 1. PLoS Curr 2010;2: RRN1177.
29. Glimelius B, Lahn M: Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann Oncol 2011;22:1717-1725.
30. Tentler JJ, Tan AC, Weekes CD, et al.: Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012;9:338-350.